logo
Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million

Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million

Reutersa day ago
July 15 (Reuters) - Hong Kong-listed Sino Biopharmaceutical (1177.HK), opens new tab said on Tuesday it will buy the remaining 95.09% stake it does not hold in Shanghai-based LaNova Medicines for no more than $950.92 million.
The acquisition of the cancer treatment developer will enhance Sino's competitiveness and influence in oncology innovation, while also enabling potential future international transactions by leveraging LaNova's R&D capabilities, it added.
Sino added LaNova will become an indirect wholly owned subsidiary once the deal is completed, which is expected within 30 business days after regulatory conditions are met.
The firm had already bought a 4.91% stake in LaNova in November, opens new tab last year, paying around 142 million yuan ($19.80 million) at the time.
LaNova Medicines was founded in 2019, specialising in discovering and developing antibody-based cancer treatments, according to details mentioned on their website.
In November last year, Merck (MRK.N), opens new tab licensed an early-stage cancer drug LM-299 from LaNova in a deal worth up to $3.3 billion, taking over its development.
The drug candidate targets the PD-1 protein, which prevents the immune system from killing cancerous cells. It also curbs levels of VEGF protein, which can encourage tumor growth if found in excess.
($1 = 7.1729 Chinese yuan renminbi)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Coats to buy US insole maker for brands including Adidas and Asics for £573m
Coats to buy US insole maker for brands including Adidas and Asics for £573m

The Independent

time13 minutes ago

  • The Independent

Coats to buy US insole maker for brands including Adidas and Asics for £573m

London-listed footwear manufacturer Coats has agreed to buy a US company that makes premium shoe insoles for 770 million US dollars (£573 million). The company said acquiring OrthoLite means it is bringing together two 'global leaders' in the industry. OrthoLite makes open-cell foam insoles, designed to be a more comfortable and sustainable lining for shoes, for a swathe of shoemakers including Adidas, Nike, Converse and Asics. It has more than a third share of the market and supplies about 500 million pairs of insoles a year to around 550 brands. Coats, which is listed on London's FTSE 250 index, is a global specialist in thread manufacturing and making components for clothes and footwear. It said it had agreed to buy OrthoLite for an enterprise value of 770 million US dollars. The acquisition will be funded through a combination of new debt facilities with its existing lenders and by raising funds from issuing new shares to investors. Coats said it would benefit from expanding into the fast-growing premium insole market where there is a big overlap with its existing footwear customers. 'The combination of Coats and OrthoLite is fantastic news for both companies and for the footwear industry,' chief executive David Paja said. 'It brings together two global leaders in adjacent segments of the footwear components sector with a shared vision for innovation and sustainability and with unparalleled brands and customer relationships.'

Fast lane
Fast lane

Reuters

time41 minutes ago

  • Reuters

Fast lane

Follow on Apple or Spotify. Listen on the Reuters app. There's a race going on between the world's two largest auto makers, China and the United States, and the People's Republic is out in front. Host Carmel Crimmins talks innovation, protectionism, competition and who gets left behind with Reuters Greater China bureau chief Kevin Krolicki and global autos editor Brian Thevenot. Tortoise economies, and hot pot in cars to come. Read the special report on China's emerging dominance in the auto sector ⁠here⁠. Sign up for the Reuters Econ World newsletter ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Sign up for the Reuters Auto File newsletter ⁠here⁠ For information on our privacy and data protection practices visit the Thomson Reuters Privacy Statement. You may also visit to opt out of targeted advertising. Further Listening China's price problem EV batteries China's 'Rotten-tail kids'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store